ICLR - ICON Public Limited Company
| Previous Close | 146.65 |
| Open | 145.86 |
| Bid | 145.81 x 800 |
| Ask | 146.03 x 900 |
| Day's Range | 145.80 - 147.34 |
| 52 Week Range | 101.22 - 150.18 |
| Volume | 92,569 |
| Avg. Volume | 221,401 |
| Market Cap | 7.921B |
| Beta | 0.20 |
| PE Ratio (TTM) | 27.10 |
| EPS (TTM) | 5.38 |
| Earnings Date | Oct 24, 2018 - Oct 29, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 154.00 |
Markit•29 days agoSee what the IHS Markit Score report has to say about ICON PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ICLR earnings conference call or presentation 26-Jul-18 1:00pm GMT
Q2 2018 ICON PLC Earnings Call
- Business Wire•2 months ago
ICON Confirms Retirement of Co-Founder Dr. Ronan Lambe
ICON plc (ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today confirmed, that Dr. Ronan Lambe retired as a non-executive director at the Annual General Meeting (AGM) of the Company on the 24th July 2018. This follows the announcement in the 2018 AGM Notice, dated 12th June 2018, that Dr. Lambe had decided to retire and not seek re-election at the AGM. CEO Dr. Steve Cutler commented, “I would like to recognize the immense contribution of Dr. Ronan Lambe, ICON’s co-founder with Dr. John Climax, who after 28 years of service, has retired from our Board.
- Associated Press•2 months ago
Icon PLC: 2Q Earnings Snapshot
On a per-share basis, the Dublin-based company said it had profit of $1.31. Earnings, adjusted for restructuring costs, came to $1.51 per share. The results exceeded Wall Street expectations. The average ...
Market Realist•2 months agoIQVIA Raised Its 2018 Guidance after Its Q2 2018 Results
IQVIA Holdings (IQV) announced its second-quarter earnings results on July 24. In the quarter, the company generated revenue of $2.6 billion, which reflected a ~9% rise YoY (year-over-year) and a 7.7% rise YoY on a constant-currency basis.
- Business Wire•2 months ago
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
ICON plc , a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company held on July 24, 2018 were all duly passed by shareholders.
Markit•2 months agoSee what the IHS Markit Score report has to say about ICON PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Zacks•2 months ago
OncoCyte (OCX) in Focus: Stock Moves 13.1% Higher
OncoCyte (OCX) was a big mover last session, as the company saw its shares rise more than 13% on the day.
- Business Wire•3 months ago
ICON Is Collaborating with Practice Fusion, Inc. to Advance Health Research
ICON plc, (ICLR) a global provider of drug development services to the pharmaceutical, biotechnology and medical device industries, today announced that it is working with Practice Fusion to leverage active patient data in support of health research. Practice Fusion, Inc., an Allscripts company, is an industry leading cloud-based ambulatory electronic health record (EHR) platform in the US, supporting more than 20,000 medical practices to deliver better care to over five million patients monthly. Practice Fusion offers connectivity solutions and services that can help make healthcare management better for everyone—including clinical labs, pharmacies, imaging centres, health systems and other US healthcare ecosystem stakeholders.
- Simply Wall St.•3 months ago
Is ICON Public Limited Company’s (NASDAQ:ICLR) 23.92% ROE Strong Compared To Its Industry?
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want a simplistic look at the returnRead More...
- Business Wire•3 months ago
ICON Enhances Endpoint Adjudication Services Using AG Mednet Advanced Technology
ICON plc (ICLR), a global provider of drug development and commercialisation solutions and services, today announced it has signed an agreement with AG Mednet to use Judi, a comprehensive electronic endpoint adjudication system to manage workflow and ensure data quality, for enhanced endpoint event adjudication services. Judi, an integrated, cloud-based SaaS tool, provides a level of flexibility that enables the implementation of the most complex endpoint and adverse event processes, delivering fewer queries, higher transparency and increased quality for clients.
Markit•3 months agoSee what the IHS Markit Score report has to say about ICON PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Business Wire•4 months ago
ICON launches FIRECREST Financial Disclosure to Reduce Administrative Costs and Increase Regulatory Compliance
ICON plc, (ICLR) a global provider of drug development and commercialisation solutions and services, today announced the launch of FIRECREST Financial Disclosure, an innovative digital solution that increases the efficiency and compliance of investigator Financial Disclosure administration. FIRECREST Financial Disclosure provides a robust solution for sponsors to distribute, track and manage the completion of forms mandated by FDA 21CFR Part 54 (Financial Disclosure by Clinical Investigators). The solution enables secure, centralised, electronic distribution and response capture of Financial Disclosure information.
- Business Wire•4 months ago
ICON Named by Forbes as One of the Best Employers in America
ICON plc, (ICLR) a global provider of drug development and commercialisation solutions and services, today announced that it has been included in Forbes magazine’s America’s Best Employers list for 2018. The Forbes list features the top 500 large employers in the US with more than 5,000 employees, and the top 500 midsize companies with 1,000 – 5,000 employees. ICON was the highest ranked CRO in the best large employers listing, and is amongst the top 10 companies in the ‘Drugs & Biotechnology’ industry sector ranking.
- Business Wire•4 months ago
Saama Technologies and ICON Commercialization and Outcomes Partner to Unlock the Value of Real World Evidence (RWE)
Saama Technologies, a leading clinical and health data analytics company, and ICON plc , a global provider of drug development and commercialization solutions and services, have partnered to accelerate the use of Real World Evidence across the product lifecycle and drive mission critical decisions for medical affairs, reimbursement and commercialization functions.
- Business Wire•4 months ago
ICON Announces Clinical Research partnership with DuPage Medical Group
ICON plc (ICLR), a global provider of drug development and commercialisation solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalised a Master Agreement formalising a clinical research partnership. Effective May 2018, PMG Research will assume the research infrastructure at the DuPage Medical Group. The expansion of the PMG Research network enhances ICON’s ability to increase access and engagement with investigator sites and patients, helping customers to reduce the overall time and cost associated with drug development.
Markit•4 months agoSee what the IHS Markit Score report has to say about ICON PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Business Wire•4 months ago
ICON Sponsors Industry-Wide Clinical Trials Survey to Support Transforming Trials Initiative
ICON plc, (ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the results from a new survey of pharmaceutical executives and professionals by ICON and Pharma Intelligence, which examines the key challenge of declining research and development (R&D) efficiency. A roundtable of pharmaceutical industry executives discussed the survey findings, alongside the key challenges affecting the pharmaceutical industry. The challenges most frequently cited by survey respondents are patient enrolment (56%), site start-up (43%) and regulatory approval delays and changes (43%).
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of ICLR earnings conference call or presentation 3-May-18 1:00pm GMT
Q1 2018 ICON PLC Earnings Call
- Associated Press•5 months ago
Icon PLC: 1Q Earnings Snapshot
On a per-share basis, the Dublin-based company said it had net income of $1.42. The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
- Business Wire•5 months ago
ICON Reports First Quarter 2018 Results
ICON plc , a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2018.
Markit•5 months agoSee what the IHS Markit Score report has to say about ICON PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ICLR totaled $248 million.
- Business Wire•5 months ago
ICON Announces Agreement with Intel Allowing Integration of the Intel® Pharma Analytics Platform for Clinical Trials
ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed on preliminary deal terms with Intel Corporation to enable ICON to offer the Intel® Pharma Analytics Platform for use in clinical trials.
